TP53 and acute myeloid leukemia: Given the critical involvement of Wnt signaling in AML pathogenesis and therapy resistance, targeting the mevalonate or Wnt pathways presents a promising strategy to overcome CAR T-cell resistance in TP53-mutant AML cells (116).